Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

glesatinib (MGCD265)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

BMS

Drug class:

VEGFR inhibitor, c-MET inhibitor, AXL inhibitor

Related drugs:

‹

sunitinib (139)

lenvatinib (90)

fruquintinib (24)

surufatinib (7)

adAptVEGF-C adenoviral vector (0)

VEGFR1-1084 (0)

BAY 57- 9352 (0)

savolitinib (29)

amivantamab-vmjw (25)

capmatinib (23)

unecritinib (6)

gumarontinib (5)

JNJ-38877605 (1)

EMD 1204831 (0)

PF-04217903 (0)

PF-07265807 (0)

›

MET mutation	Non Small Cell Lung Cancer	MET mutation	Non Small Cell Lung Cancer	MGCD265 Sensitive: C2 – Inclusion Criteria MGCD265 Sensitive : C2	MGCD265 Sensitive: C2 – Inclusion Criteria MGCD265 Sensitive : C2
MET exon 14 deletion	Non Small Cell Lung Cancer	MET exon 14 deletion	Non Small Cell Lung Cancer	MGCD265 Sensitive: C3 – Early Trials MGCD265 Sensitive : C3	MGCD265 Sensitive: C3 – Early Trials MGCD265 Sensitive : C3
MET amplification + AXL amplification	Non Small Cell Lung Cancer	MET amplification + AXL amplification	Non Small Cell Lung Cancer	MGCD265 Sensitive: C3 – Early Trials MGCD265 Sensitive : C3	MGCD265 Sensitive: C3 – Early Trials MGCD265 Sensitive : C3
MET mutation + AXL mutation	Non Small Cell Lung Cancer	MET mutation + AXL mutation	Non Small Cell Lung Cancer	MGCD265 Sensitive: C3 – Early Trials MGCD265 Sensitive : C3	MGCD265 Sensitive: C3 – Early Trials MGCD265 Sensitive : C3